A5018797024- COVID-19 Clinical Research Studies
- Cardiovascular and exercise physiology
- Cardiovascular Health and Disease Prevention
- Chronic Kidney Disease and Diabetes
- Diabetes Treatment and Management
- Dialysis and Renal Disease Management
- Heart Failure Treatment and Management
- Erythropoietin and Anemia Treatment
- Cardiovascular Effects of Exercise
- Vitamin D Research Studies
Age UK
2024
University of Cambridge
2024
Key Points Patients with CKD face meaningful risk of heart failure hospitalization. Daprodustat compared darbepoetin was associated a nonsignificantly greater number hospitalizations in non-dialysis patients. Background are at higher failure. The hypoxia-inducible factor prolyl hydroxylase inhibitor daprodustat is an orally acting alternative to conventional injectable erythropoietin-stimulating agents (ESAs) for the treatment anemia patients CKD. Whether affects hospitalization unknown....
Key Points Mild-to-moderate CKD is associated with impairment in cardiovascular functional capacity as assessed by oxygen uptake at peak exercise (VO 2 Peak). Cardiac output significantly reduced patients mild-to-moderate and impaired VO Peak. Assessment of Peak cardiopulmonary testing can detect decrements function during early stages kidney decline that may not be captured using resting left ventricular geometric indices alone. Background Traditional diagnostic tools assess cardiac...